Compare · DXCM vs ICCM
DXCM vs ICCM
Side-by-side comparison of DexCom Inc. (DXCM) and IceCure Medical Ltd. (ICCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and ICCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 2893.9x ICCM ($10.2M).
- Over the past year, DXCM is down 10.6% and ICCM is down 87.9% - DXCM leads by 77.3 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 6 for ICCM).
- DXCM has more recent analyst coverage (25 ratings vs 2 for ICCM).
- Company
- DexCom Inc.
- IceCure Medical Ltd.
- Price
- $76.59+5.15%
- $3.69-15.17%
- Market cap
- $29.57B
- $10.2M
- 1M return
- +25.71%
- -50.92%
- 1Y return
- -10.56%
- -87.88%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 6
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 4 filed by VP, R&D & Engineering Muchnik Naum
- New insider Peleg Meir claimed ownership of 400,000 units of Ordinary shares (SEC Form 3)
- SEC Form 4 filed by Chief Financial Officer Tsimerman Ronen
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
- SEC Form 424B5 filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.